THESEUS PHARMACEUTICALS INC (THRX) Stock Price, Quote, News and Overview
NASDAQ:THRX - Nasdaq - US88369M1018 - Common Stock - Currency: USD
THRX Quote, Performance and Key Statistics
4.06
0 (0%)
The current stock price of THRX is 4.06 USD. In the past month the price increased by 1.75%. In the past year, price decreased by -64.45%.
THRX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 67.21 | 829.40B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 27.44 | 390.99B | ||
| JNJ | JOHNSON & JOHNSON | 16.25 | 390.76B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 20.56 | 230.17B | ||
| MRK | MERCK & CO. INC. | 11.71 | 226.40B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.77 | 215.98B | ||
| PFE | PFIZER INC | 8.46 | 149.04B | ||
| SNY | SANOFI-ADR | 13.58 | 136.54B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 48.97 | 113.23B | ||
| GSK | GSK PLC-SPON ADR | 7.78 | 74.77B | ||
| ZTS | ZOETIS INC | 27.1 | 72.39B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 31.95 | 44.58B |
Related stock screener links
About THRX
Company Profile
Theseus Pharmaceuticals, Inc. engages in the development of pan-variant kinase inhibitors. The company is headquartered in Cambridge, Massachusetts and currently employs 38 full-time employees. The company went IPO on 2021-10-07. The company is focused on treating cancer patients through the discovery, development, and commercialization of targeted therapies. Its development programs are designed to address drug resistance mutations in key driver oncogenes, which are mutated genes that cause cancer. The company also focused on tyrosine kinase inhibitors (TKIs), which is rooted in the critical role that tyrosine kinases play in the development of cancer. The company develops pan-variant kinase inhibitors-inhibitors that target cancer-causing and drug resistance mutations in clinically protein kinases. Its product candidate, THE-630, is a pan-variant inhibitor of all classes of activating and resistance mutations of the KIT kinase for the treatment of GIST, a type of cancer often characterized by oncogenic activation of KIT. The company is also developing THE-349, a selective epidermal growth factor receptor inhibitor for the treatment of non-small cell lung cancer.
Company Info
THESEUS PHARMACEUTICALS INC
314 Main Street, Suite 04-200
Cambridge MASSACHUSETTS 94080 US
CEO: Michael W. Aguiar
Employees: 38
Company Website: https://theseusrx.com/
Phone: 18574009491
THESEUS PHARMACEUTICALS INC / THRX FAQ
What is the stock price of THESEUS PHARMACEUTICALS INC today?
The current stock price of THRX is 4.06 USD.
What is the ticker symbol for THESEUS PHARMACEUTICALS INC stock?
The exchange symbol of THESEUS PHARMACEUTICALS INC is THRX and it is listed on the Nasdaq exchange.
On which exchange is THRX stock listed?
THRX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for THESEUS PHARMACEUTICALS INC stock?
9 analysts have analysed THRX and the average price target is 5.36 USD. This implies a price increase of 31.9% is expected in the next year compared to the current price of 4.06. Check the THESEUS PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is THESEUS PHARMACEUTICALS INC worth?
THESEUS PHARMACEUTICALS INC (THRX) has a market capitalization of 181.28M USD. This makes THRX a Micro Cap stock.
How many employees does THESEUS PHARMACEUTICALS INC have?
THESEUS PHARMACEUTICALS INC (THRX) currently has 38 employees.
What are the support and resistance levels for THESEUS PHARMACEUTICALS INC (THRX) stock?
THESEUS PHARMACEUTICALS INC (THRX) has a support level at 3.64 and a resistance level at 4.07. Check the full technical report for a detailed analysis of THRX support and resistance levels.
Should I buy THESEUS PHARMACEUTICALS INC (THRX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of THRX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of THRX, evaluating the profitability, health, valuation and growth aspects
- THESEUS PHARMACEUTICALS INC (THRX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- THESEUS PHARMACEUTICALS INC (THRX) Sales and EPS estimates to see what analysts future expectations are.
- THESEUS PHARMACEUTICALS INC (THRX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- THESEUS PHARMACEUTICALS INC (THRX) Insider and Institutional Ownership to learn about the owners and their transactions.
- THESEUS PHARMACEUTICALS INC (THRX) Stock Chart to make your own analysis
- THESEUS PHARMACEUTICALS INC (THRX) Latest news and press-releases to stay up to date.
Does THESEUS PHARMACEUTICALS INC (THRX) stock pay dividends?
THRX does not pay a dividend.
When does THESEUS PHARMACEUTICALS INC (THRX) report earnings?
THESEUS PHARMACEUTICALS INC (THRX) will report earnings on 2024-03-07, after the market close.
What is the Price/Earnings (PE) ratio of THESEUS PHARMACEUTICALS INC (THRX)?
THESEUS PHARMACEUTICALS INC (THRX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.34).
THRX Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to THRX. When comparing the yearly performance of all stocks, THRX is a bad performer in the overall market: 86.76% of all stocks are doing better.
THRX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to THRX. While THRX has a great health rating, there are worries on its profitability.
THRX Financial Highlights
Over the last trailing twelve months THRX reported a non-GAAP Earnings per Share(EPS) of -1.34. The EPS decreased by -12.61% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -24.13% | ||
| ROE | -25.22% | ||
| Debt/Equity | 0 |
THRX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 78% to THRX. The Buy consensus is the average rating of analysts ratings from 9 analysts.